Indications for: REPRONEX 75 IU
Multiple follicular development for in vitro fertilization and ovulation induction in women who have previously received pituitary suppression.
For controlled ovarian hyperstimulation: 150 IU daily for 1st 5 days of treatment, followed by 5000–10000 Units of hCG 1 day after last dose. ART: Initially 225 IU followed by 5000–10000 Units of hCG. For both: Adjust in increments of 75–150 IU at intervals of at least 2 days; max 450 IU/day and 12 days treatment.
REPRONEX 75 IU Contraindications:
Primary ovarian failure. Uncontrolled thyroid or adrenal dysfunction. Intracranial lesions. Undiagnosed abnormal vaginal bleeding. Ovarian cysts or enlargement. Pregnancy (Cat.X).
REPRONEX 75 IU Warnings/Precautions:
Be fully familiar with infertility treatment and its complications before using this product. Do complete gynecological and endocrinological exam first. Monitor appropriate lab values. May cause false (+) pregnancy test. Thromboembolic disorders. If ovaries are excessively enlarged on last day of therapy do not administer hCG; this decreases risk of ovarian hyperstimulation syndrome (OHSS). Discontinue if OHSS occurs. Nursing mothers.
OHSS with pulmonary and vascular complications, hemoperitoneum, adnexal torsion, ovarian enlargement or cysts, abdominal pain, flu-like symptoms, GI disturbances, local reactions, rash, dizziness, tachycardia, dyspnea, tachypnea, risk of high order multiple births.